BioE to Participate in Launch of International Research Consortium on Cord Blood and Adult Stem Cells for Therapeutic Applications

BioE^®, Inc., a biomedical company that provides enabling, high-quality human stem cells for drug discovery and therapeutic research, announced today Gayl Chrysler, vice president of cellular technologies and clinical affairs for BioE, will participate in the launch of Novussanguis, an international research consortium on cord blood and adult stem cells for therapeutic applications, in Paris, France on Wed., May 14.

To be unveiled at the Medical School of University Paris Descartes, the Novussanguis consortium will consist of approximately 15 regenerative medicine and cell therapy laboratories around the world. Novussanguis was co-founded by BioE research collaborator Professor Colin McGuckin and his team at Newcastle University (Great Britain) and the Foundation Jérôme Lejeune in Paris. BioE’s Chrysler was invited to the Novussanguis launch to serve on a panel about innovation, commercialization and patentability of regenerative medicine and cell therapy given BioE’s experience commercializing its cord blood stem cell, the Multi-Lineage Progenitor Cell™ (MLPC™).

“It is an honor to support the efforts of Novussanguis,” Chrysler said. “This research consortium has the potential to collaboratively identify workable stem cell solutions for treating a wide variety of diseases and conditions. In the ever evolving field of stem cell research, more transparent and coordinated research is what is going to advance the science quicker and ultimately improve the lives of patients.”

During the past three years, more than 100 academic research institutions, corporate laboratories and pharmaceutical organizations globally have licensed the MLPC from BioE for stem cell and regenerative medicine research purposes. BioE also is engaged in collaborative stem cell research partnerships to further understand the potential therapeutic applications of the MLPC.